The U.S. synthetic biology market size was estimated at USD 6.45 billion in 2025 and is projected to be worth around USD 27.97 billion by 2035, expanding at a CAGR of 15.8% from 2026 to 2035. Advancements in technologies such as CRISPR, DNA synthesis , and AI integration are some of the major market growth factors.

U.S. Synthetic Biology Market Statical Scope

The U.S. synthetic biology market is also observed to grow due to higher demand for personalized medicine , sustainable bio-based products, accelerated development cycles, for vaccines and drugs. Use of leading technologies such as PCR technology, genome editing , NGS technology, and bioprocessing is also one of the major market drivers.

U.S. Synthetic Biology Market, By Product Outlook 2025 (%)

• Oligonucleotide / Oligo Pools & Synthetic DNA- The segment has a significant market share of 28% and is driven by strong demand for gene synthesis, sequencing, and advanced genetic engineering applications.
• Enzymes- The segment accounts for 24% of the market share, and its growth is supported by its critical role in DNA manipulation, amplification, and widespread use across biology workflows.
• Cloning Technologies Kits- The segment has a notable share of 16% of the market and is supported by consistent research activity, along with growing demand for efficient genetic modification tools.

U.S. Synthetic Biology Market, By Technology Outlook 2025 (%)

• NGS Technology- The segment has a significant market share of 22% and is supported by growing demand for high-throughput sequencing and genomic analysis.
• PCR Technology- The segment has a notable market share of 18% and is supported by its vital role in diagnostics and molecular biology research.
• Genome Editing Technology- The segment has 26% of the market share and is propelled due to strong adoption of advanced technology such as CRISPR-based tools for precision medicine , gene therapy , and agricultural innovation.

U.S. Synthetic Biology Market, By Application Outlook 2025 (%)

• Healthcare - The segment accounts for a significant market share of 46% due to its increasing usage in drug development, gene therapy, and precision medicine applications.
• Non-Healthcare - The segment holds for 54% of the market share and is driven by strong adoption in domains such as industrial biotechnology , agriculture, and bio-based chemical production.

U.S. Synthetic Biology Market, By End Use Outlook 2025 (%)

• Biotechnology and Pharmaceutical Companies - The segment has a dominant market share of 52% and is driven by high investments for R&D, along with strong integration of synthetic biotechnology in drug discovery and production.
• Academic and Research Institutes - The segment has a notable market share of 33% as it is supported by strong research funding and innovation-driven studies.

Top Companies in the U.S. Synthetic Biology Market

• Bota Biosciences Inc.
• Codexis, Inc.
• Creative Biogene.
• Creative Enzymes.
• Enbiotix, Inc.
• Illumina, Inc.
• Merck Kgaa (Sigma-Aldrich Co. Llc)
• New England Biolabs
• Eurofins Scientific
• Novozymes
• Pareto Bio, Inc.
• Scarab Genomics, Llc
• Synthego
• Synthetic Genomics Inc.
• Thermo Fisher Scientific, Inc.

Segments Covered in the Report

By Product

• Oligonucleotide/Oligo Pools and Synthetic DNA
• Enzymes
• Cloning Technologies Kits
• Xeno-Nucleic Acids
• Chassis Organism

By Technology

• NGS Technology
• PCR Technology
• Genome Editing Technology
• Bioprocessing Technology
• Other Technologies

By Application

• Healthcare
  • Clinical
    • Bio/Pharmaceuticals
    • Diagnostics
  • Non-Clinical
• Non-healthcare
  • Biotech Crops
  • Specialty Chemicals
  • Bio-fuels
  • Others

By End Use

• Biotechnology and Pharmaceutical companies
• Academic and Research Institutes
• Others